KOD Kodiak Sciences

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Company profile

Victor Perlroth
Fiscal year end
Former names
Oligasis, LLC
IRS number

KOD stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


10 May 21
18 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 926.79M 926.79M 926.79M 926.79M 926.79M 926.79M
Cash burn (monthly) 7.98M (positive/no burn) 16.85M 13.4M 11.54M 8.34M
Cash used (since last report) 12.66M n/a 26.74M 21.27M 18.32M 13.24M
Cash remaining 914.12M n/a 900.04M 905.51M 908.47M 913.54M
Runway (months of cash) 114.6 n/a 53.4 67.6 78.7 109.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 May 21 Ehrlich Jason Common Stock Option exercise Aquire M No No 10 1,889 18.89K 70,111
12 May 21 Ehrlich Jason Common Stock Option exercise Aquire M No No 10.29 5,379 55.35K 68,222
12 May 21 Ehrlich Jason Stock Option Common Stock Option exercise Dispose M No No 10 1,889 18.89K 54,793
12 May 21 Ehrlich Jason Stock Option Common Stock Option exercise Dispose M No No 10.29 5,379 55.35K 258,546
20 Apr 21 Ehrlich Jason Common Stock Sell Dispose S No Yes 114.9729 182 20.93K 62,843
20 Apr 21 Ehrlich Jason Common Stock Sell Dispose S No Yes 113.7263 595 67.67K 63,025
20 Apr 21 Ehrlich Jason Common Stock Sell Dispose S No Yes 112.1522 669 75.03K 63,620
20 Apr 21 Ehrlich Jason Common Stock Sell Dispose S No Yes 111.3087 3,650 406.28K 64,289
20 Apr 21 Ehrlich Jason Common Stock Sell Dispose S No Yes 110.3726 621 68.54K 67,939
20 Apr 21 Ehrlich Jason Common Stock Sell Dispose S No Yes 109.3341 1,233 134.81K 68,560

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

85.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 175 138 +26.8%
Opened positions 59 28 +110.7%
Closed positions 22 16 +37.5%
Increased positions 58 46 +26.1%
Reduced positions 47 44 +6.8%
13F shares
Current Prev Q Change
Total value 6.75B 2.79B +142.5%
Total shares 43.89M 36.87M +19.1%
Total puts 82.6K 353.3K -76.6%
Total calls 328K 53.1K +517.7%
Total put/call ratio 0.3 6.7 -96.2%
Largest owners
Shares Value Change
Baker Bros. Advisors 13.88M $2.04B +12.4%
TROW T. Rowe Price 6.18M $907.35M +25.8%
Wellington Management 4.48M $658.46M +45.5%
BLK Blackrock 3.09M $453.96M +14.9%
Vanguard 2.84M $416.58M +18.5%
Hillhouse Capital Advisors 1.16M $170.04M NEW
ICONIQ Capital 1.13M $165.9M -34.7%
STT State Street 1.13M $165.42M -8.5%
ArrowMark Colorado 972.3K $142.84M -21.7%
FMR 755.47K $110.99M +110.9%
Largest transactions
Shares Bought/sold Change
Baker Bros. Advisors 13.88M +1.53M +12.4%
Wellington Management 4.48M +1.4M +45.5%
TROW T. Rowe Price 6.18M +1.27M +25.8%
Hillhouse Capital Advisors 1.16M +1.16M NEW
ICONIQ Capital 1.13M -600K -34.7%
Vanguard 2.84M +442.05K +18.5%
IVZ Invesco 436.14K +436.14K NEW
BLK Blackrock 3.09M +401.52K +14.9%
FMR 755.47K +397.34K +110.9%
Norges Bank 381.47K +381.47K NEW

Financial report summary

  • Our prospects are heavily dependent on our KSI-301 product candidate, which is currently in clinical development for multiple indications.
  • A failure of KSI-301 in clinical development may require us to discontinue development of other product candidates based on our ABC Platform.
  • We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.
  • Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
  • We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.
  • We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited.
  • We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may retain their market share with existing drugs, or achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.
  • The manufacture of our product candidates is highly complex and requires substantial lead time to produce.
  • We have no experience manufacturing any of our product candidates at a commercial scale. If we or any of our third-party manufacturers encounter difficulties in production, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to establish a commercially viable cost structure.
  • If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.
  • Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
  • Our product candidates may face competition from biological products that are biosimilar to or interchangeable with our product candidates sooner than anticipated.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • The regulatory approval processes of the FDA, EMA, NMPA and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.
  • We plan to conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, NMPA and applicable foreign regulatory authorities may not accept data from such trials.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.
  • If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.
  • Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.
  • If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
  • We contract with third parties for the manufacture of materials for our product candidates and preclinical studies and clinical trials and for commercialization of any product candidates that we may develop. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
  • Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • We rely on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.
  • If we are unable to obtain and maintain patent protection for any product candidates we develop or for our ABC Platform, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.
  • If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Issued patents may be challenged or invalidated, and recent changes in U.S. patent law have diminished and may further diminish the value of patents in general. We rely on patents to protect our products, and any diminishment in the scope or value of our patents would adversely affect our business.
  • If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
  • We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
  • Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
  • Our business is subject to economic, political, regulatory and other risks associated with international operations.
  • Our business is currently affected and could be materially and adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics, including the ongoing effects of the COVID-19 pandemic. The COVID-19 pandemic continues to impact our business and could materially and adversely affect our operations, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • We are in the clinical stage of drug development and have a very limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.
  • We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur significant and increasing net losses for the foreseeable future.
  • Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on product candidates that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
  • If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
  • Future sales of our common stock in the public market could cause our share price to decline, even if our business is doing well.
  • A failure to maintain an effective system of internal control over financial reporting could result in material misstatements of our financial statements in future periods and may impair our ability to comply with the accounting and reporting requirements applicable to public companies. Furthermore, our business, financial position, and results of operations could be adversely affected.
Management Discussion
  • Research and development expenses increased $69.9 million, or 186%, from the year ended December 31, 2019 to the year ended December 31, 2020.
  • ABC Platform external expenses increased $5.1 million during the year ended December 31, 2020 as compared to 2019. The increase was primarily driven by manufacturing runs to support our product candidate pipeline.
  • KSI-301 program external expenses increased $39.3 million during the year ended December 31, 2020 as compared to 2019, primarily due to clinical trial costs to support ongoing trials, as well as manufacturing activities for KSI-301. Our pivotal Phase 2b/3 clinical study in wAMD (DAZZLE) dosed the first patient in October 2019, and patient recruitment completed in the fourth quarter of 2020. We initiated two pivotal Phase 3 clinical studies in DME (GLEAM and GLIMMER) and one pivotal Phase 3 clinical study in RVO (BEACON) in the third quarter of 2020.
Content analysis
H.S. junior Avg
New words: Addendum, affiliated, aflibercept, anesthesiologist, annum, ballot, begun, Beovu, Biden, Britain, broader, broadest, choroidal, CMC, codification, constitutionality, convertible, CPRA, credential, cybercrime, cybersecurity, DAYLIGHT, deal, delete, deny, distancing, diverge, dosage, Edition, engine, engineering, espionage, ESPP, expansion, exploited, faricimab, Felix, fundamentally, genetic, Germany, hacking, honor, iii, immaterial, incident, instructed, Israel, legislature, lesser, life, malware, mechanism, merge, MHRA, molecular, myopic, nationwide, neovascularization, NMPA, Northern, notify, overturning, path, perspective, phishing, pipette, plant, preliminary, principle, proportion, qualification, ransomware, ratably, reconsider, redeemable, regime, resale, scarce, slightly, slower, social, softer, spanning, sterile, stuffing, syringe, tariff, topline, transmit, twelve, unexpected, unnecessary, uptake, vaccine, waiver, window
Removed: acceleration, accrete, achieved, activate, activated, advisory, affecting, affinity, afford, allotted, alveolar, Ancillary, Arrangement, assembling, assessed, attestation, audit, auditor, avoiding, balance, basket, Bay, billion, blockade, Blueprint, branch, building, built, calendar, cancelable, capped, certiorari, clinic, cloud, CMS, codified, component, computing, confirmed, constant, continually, convince, cyber, damaged, devoted, differentiated, direct, documented, dosed, dysfunction, effector, elevated, emerging, enable, Endothelial, enthusiasm, essentially, establishment, exemplified, exemption, explored, extraordinary, Factor, fall, Fc, finance, firm, footing, fourth, Francisco, functioning, fusion, GMP, golden, hacker, harder, HHS, holding, home, hour, immune, immunologic, immunologically, implicated, implicit, improved, improvement, impute, imputed, inappropriate, inducer, inert, inflammatory, inhibition, inhibitor, interleukin, intermediate, intersection, Intriguingly, irrevocable, irrevocably, Jumpstart, kidney, lend, letter, licensure, listed, logistical, lung, manageable, marginal, matched, meaningfully, mediated, modification, narrowing, Nasdaq, NDA, necessitated, nonbinding, NPDR, opening, ophthalmology, opt, optimized, oral, paired, parachute, partnering, pathological, payable, periodically, permeability, pocket, predictable, proceed, project, proposal, protein, pulmonary, ranging, rating, reaction, recovery, refer, reflection, registrational, remained, repay, repurchased, resultant, role, rotation, running, San, scaled, secure, Simplifying, Society, sophistication, specificity, step, Street, Subtopic, supplement, supporting, switch, synergistic, systemically, testament, thoughtful, tissue, top, Topic, unique, unobservable, unrealized, Updated, upfront, upgraded, usage, validate, view, Wall, weighted, worsening